Share
Save
Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult
This is a Phase I/IIa Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVII in Healthy Adult Volunteers.
Study details:
Subjects will undergo a Screening period beginning up to 2 weeks prior to enrollment, the vaccinations will be administered on week 0 and week 3, pre- and post-dose assessment, follow-up visits, and an end of study (EOS) or early termination (ET) visit (as applicable).
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
Exclusion criteria
Eligibility
Age eligible for study : 18 and older
Healthy volunteers accepted : Yes
Gender eligible for study: All
Things to know
Study dates
Study start: 2023-10-23
Primary completion: 2024-04-01
Study completion finish: 2024-07-01
Study type
PREVENTION
Phase
PHASE1
PHASE2
Trial ID
NCT06099613
Intervention or treatment
BIOLOGICAL: EG-COVII
Conditions
- • COVID-19
Find a site
Closest Location:
Nucleus Network Pty Ltd- Melbourne
Research sites nearby
Select from list below to view details:
Nucleus Network Pty Ltd- Melbourne
Melbourne, Victoria, Australia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Participant Group/Arm | Intervention/Treatment |
---|---|
EXPERIMENTAL: EG-COVII
| BIOLOGICAL: EG-COVII
|
What is the study measuring?
Primary outcome
Primary Outcome Measure | Primary Outcome Description | Primary Outcome Time Frame |
---|---|---|
Safety and tolerability of EG-COVII in healthy adult volunteers | Number of participants with adverse events (AEs) Number of participants with abnormal clinical laboratory results (hematology /chemistry /urinalysis) Number of participants with abnormal vital sign Number of participants with abnormal physical examination results | 7 weeks follow up |
Secondary outcome
Frequently Asked Questions
Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol
No questions submitted. Be the first to ask a question!